Skip to main content
. 2017 Aug 1;8(45):79809–79815. doi: 10.18632/oncotarget.19748

Figure 1. Kaplan-Meier overall survival (OS) curves according to biomarkers and therapies.

Figure 1

(A) OS according to baseline relative eosinophil count (REC). REC < 1.5%: dotted lines; REC ≥ 1.5%: solid lines. (B) OS according to baseline relative lymphocyte count (RLC). RLC < 17.5%: dotted lines; RLC ≥ 17.5%: solid lines. Black lines: chemotherapy-treated patients (cohort A); grey lines: anti-CTLA-4-treated patients (cohort B).